Literature DB >> 7682430

Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cells.

R S Camplejohn1, A Brock, D M Barnes, C Gillett, B Raikundalia, H Kreipe, M R Parwaresch.   

Abstract

There is considerable interest in immunohistochemical markers of proliferation which are suitable for use on routinely fixed clinical material. The novel proliferation-associated antibody Ki-S1 shows promise in this respect. In this study we have: (i) defined the pattern of Ki-S1 labelling relative to the cell cycle phase; (ii) investigated the labelling pattern with Ki-S1 on a human breast cell line (ZR75) under varying proliferative conditions induced by serum deprivation and refeeding; (iii) examined in a flow cytometric study Ki-S1 staining in archival, clinical breast carcinoma samples. In exponentially growing cells Ki-S1 showed a marked cell cycle phase-specific variation in staining intensity which increased linearly through the S-phase, was high in G2 and reached its peak in mitosis. Ki-S1 staining intensity mirrored the changes in proliferative activity of ZR75 cells during serum deprivation and refeeding. In a small series of human breast carcinoma, Ki-S1 staining intensity correlated with S-phase fraction (SPF) derived from DNA profiles. The antigen labelled by Ki-S1 is extremely robust, resisting degradation by fixation and by an aggressive enzymic tissue disaggregation method. Ki-S1 warrants further investigation as a proliferation-related marker, particularly for routine clinical application.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682430      PMCID: PMC1968331          DOI: 10.1038/bjc.1993.122

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  22 in total

1.  Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry.

Authors:  S M O'Reilly; R S Camplejohn; D M Barnes; R R Millis; R D Rubens; M A Richards
Journal:  J Clin Oncol       Date:  1990-12       Impact factor: 44.544

2.  Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67.

Authors:  J Gerdes; L Li; C Schlueter; M Duchrow; C Wohlenberg; C Gerlach; I Stahmer; S Kloth; E Brandt; H D Flad
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

Review 3.  The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables.

Authors:  C M Quinn; N A Wright
Journal:  J Pathol       Date:  1990-02       Impact factor: 7.996

4.  Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count.

Authors:  J J Isola; H J Helin; M J Helle; O P Kallioniemi
Journal:  Cancer       Date:  1990-03-01       Impact factor: 6.860

5.  Ki-67 immunostaining in human breast tumors and its relationship to prognosis.

Authors:  H O Wintzer; I Zipfel; J Schulte-Mönting; U Hellerich; S von Kleist
Journal:  Cancer       Date:  1991-01-15       Impact factor: 6.860

6.  Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.

Authors:  P A Hall; D A Levison; A L Woods; C C Yu; D B Kellock; J A Watkins; D M Barnes; C E Gillett; R Camplejohn; R Dover
Journal:  J Pathol       Date:  1990-12       Impact factor: 7.996

7.  KiS1--a novel monoclonal antibody which recognizes proliferating cells: evaluation of its relationship to prognosis in mammary carcinoma.

Authors:  S A Sampson; H Kreipe; C E Gillett; P Smith; M A Chaudary; A Khan; K Wicks; R Parwaresch; D M Barnes
Journal:  J Pathol       Date:  1992-10       Impact factor: 7.996

8.  Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma.

Authors:  G Gasparini; S Dal Fior; F Pozza; P Bevilacqua
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

9.  Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form.

Authors:  N H Waseem; D P Lane
Journal:  J Cell Sci       Date:  1990-05       Impact factor: 5.285

10.  Ki-67 labeling index in breast cancer.

Authors:  S Crispino; A Brenna; D Colombo; B Flores; S D'Amico; P Lissoni; S Barni; F Paolorossi; G Bratina; G Tancini
Journal:  Tumori       Date:  1989-12-31
View more
  8 in total

1.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies.

Authors:  F Boege; A Andersen; S Jensen; R Zeidler; H Kreipe
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

2.  Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study.

Authors:  P Rudolph; U Kellner; A Chassevent; F Collin; F Bonichon; R Parwaresch; J M Coindre
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

3.  Pleomorphic xanthoastrocytomas: immunohistochemistry, grading and clinico-pathologic correlations. An analysis of 34 cases from a single Institute.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

4.  Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma.

Authors:  P Bevilacqua; P Verderio; M Barbareschi; E Bonoldi; P Boracchi; P Dalla Palma; G Gasparini
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Comparison of three cell cycle associated antigens as markers of proliferative activity and prognosis in breast carcinoma.

Authors:  C E Gillett; D M Barnes; R S Camplejohn
Journal:  J Clin Pathol       Date:  1993-12       Impact factor: 3.411

6.  Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

Authors:  P Rudolph; T Lappe; C Schubert; D Schmidt; R M Parwaresch; E Christophers
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 7.  Clinical validity and clinical utility of Ki67 in early breast cancer.

Authors:  Hans Kreipe; Nadia Harbeck; Matthias Christgen
Journal:  Ther Adv Med Oncol       Date:  2022-09-08       Impact factor: 5.485

8.  The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma.

Authors:  S A Rasbridge; C E Gillett; A M Seymour; K Patel; M A Richards; R D Rubens; R R Millis
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.